These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 2402310)

  • 1. EPO--one year later: a look at rehabilitation. Patient attitude key in impacting the job rate.
    Antonoff A
    Nephrol News Issues; 1990 Jun; 4(6):33-4, 48. PubMed ID: 2402310
    [No Abstract]   [Full Text] [Related]  

  • 2. EPO--one year later: a look at rehabilitation. Does EPO impact on rehabilitation of the dialysis patient? A nursing perspective.
    Stevenson K; Binkley LS
    Nephrol News Issues; 1990 Jun; 4(6):30-1. PubMed ID: 2402309
    [No Abstract]   [Full Text] [Related]  

  • 3. EPO--one year later: a look at rehabilitation. A patient perspective--from patients.
    Harper G
    Nephrol News Issues; 1990 Jun; 4(6):40, 46. PubMed ID: 2402311
    [No Abstract]   [Full Text] [Related]  

  • 4. EPO and renal nutrition--one year later. Evidence lacking in appetite improvement.
    Ellis PW
    Nephrol News Issues; 1990 Jun; 4(6):26, 29, 38. PubMed ID: 2402308
    [No Abstract]   [Full Text] [Related]  

  • 5. Keeping your job with kidney disease.
    Nephrol News Issues; 2005 Jun; 19(7):S3, S6. PubMed ID: 16008028
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vital indication for erythropoietin in a chronic haemodialysis patient. A case report.
    Nielsen OJ; Thaysen JH
    Dan Med Bull; 1989 Dec; 36(6):590-2. PubMed ID: 2612227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological characterization of recombinant human erythropoietin.
    Krumwieh D; Arnold I; Seiler FR
    Behring Inst Mitt; 1988 Aug; (83):193-201. PubMed ID: 3240225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients.
    Churchill DN; Muirhead N; Goldstein M; Posen G; Fay W; Beecroft ML; Gorman J; Taylor DW
    Clin Nephrol; 1995 Mar; 43(3):184-8. PubMed ID: 7774076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant erythropoietin. The effect of the marketplace on socialized patient care.
    Besarab A; Erslev AJ
    ASAIO J; 1993; 39(2):85-6. PubMed ID: 8324265
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical application of recombinant erythropoietin in predialysis renal failure.
    Briggs WA; Gimenez LF
    Hematol Oncol Clin North Am; 1994 Oct; 8(5):927-32. PubMed ID: 7852215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
    Hussein MM; Mooij JM; Roujouleh H
    Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
    [No Abstract]   [Full Text] [Related]  

  • 13. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic occult intra-alveolar hemorrhage: a rare cause of failure to respond to erythropoietin.
    Conlon PJ; O'Neill S; O'Neill G; Kelly F; Donohoe J
    Clin Nephrol; 1994 Feb; 41(2):83-5. PubMed ID: 8004833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney patient job retention: the next rehabilitation frontier.
    Schatell D; Witten B
    Nephrol News Issues; 2006 Apr; 20(4):47-8, 62. PubMed ID: 16629357
    [No Abstract]   [Full Text] [Related]  

  • 16. Correction of anaemia in haemodialysis patients with recombinant human erythropoietin.
    Boran M; Dalva I; Yazicioğlu A; Akbay E; Cetin S
    Int Urol Nephrol; 1993; 25(2):197-203. PubMed ID: 8365853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant human erythropoietin administration improves thiamine content in blood and erythrocytes transketolase activity in pre-dialyzed patients.
    Pietrzak I; Baczyk K; Kubiak W
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():29-37. PubMed ID: 8192530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Influence of long-term human recombinant erythropoietin treatment on secretion of pancreatic polypeptide and gastrin in hemodialysed patients with chronic renal failure].
    Nieszporek T; Kokot F; Wiecek A; Marcinkowski W; Rudka R; Trembecki J
    Przegl Lek; 1995; 52(12):590-3. PubMed ID: 8834657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growing pains for Amgen as epoetin wins US approval.
    Anderson A
    Nature; 1989 Jun; 339(6225):493. PubMed ID: 2733774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.